Apple Extract: A whole-apple extract standardized to 15% fisetin within a natural polyphenol matrix of quercetin, chlorogenic acid, and procyanidins. Administered as a 100 mg capsule taken orally once daily with breakfast for 24 weeks.
Placebo: An identical, matching inactive look-alike capsule containing microcrystalline cellulose. Administered orally once daily with breakfast for 24 weeks.
Study summary
The goal of this clinical trial is to learn if AppleX™ Apple Extract can help lower systemic inflammation in adults aged 45-70 with signs of low-grade inflammation. It will also look at the extract's effects on fatigue, joint comfort, and biological aging metrics.
The main questions it aims to answer are:
* Does taking AppleX™ Apple Extract daily lower high-sensitivity C-reactive protein (hsCRP) levels, a key marker of inflammation in the blood?
* Does AppleX™ Apple Extract improve participant-reported fatigue and joint comfort?
* Does the extract slow down biological or epigenetic aging metrics compared to a placebo?
Researchers will compare AppleX™ Apple Extract to a placebo (a look-alike capsule that contains no active ingredients) to see if the apple extract has a measurable anti-inflammatory and healthy aging effect.
Eligibility
Sex
ALL
Min age
45 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Age 45-70 years at time of enrollment
* Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2)
* Non-smoker (no tobacco or nicotine use within 6 months of enrollment)
* Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period
* No major medication changes planned during the study period
* Willing to perform home-based DBS collections at T0, T12, and T24
* Access to a smartphone or computer to complete eConsent and online questionnaires
* Able to provide informed consent via the Alethios eConsent platform
Exclusion Criteria:
* Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x/week), corticosteroids, or DMARDs
* Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis)
* Active or unstable cardiovascular disease requiring medication changes during the study period
* History of cancer within the past 5 years (except non-melanoma skin cancer)
* Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment
* Pregnancy, breastfeeding, or planning to become pregnant during the study
* Known allergy to apple or apple-derived products
* Body mass index (BMI) \>40 kg/m²
Primary outcome measure(s)
Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 24 — Baseline (Week 0) and Week 24 Evaluation of systemic inflammation via high-sensitivity C-reactive protein levels quantified from dried blood spot micro-sampling.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.